Tolvaptan Modifies Patient Risk Class Distribution Over Time in Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Data From the TEMPO 3:4 Trial
Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 161-162
10.1681/asn.20223311s1161d